Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone

Sci Transl Med. 2016 May 25;8(340):340ra73. doi: 10.1126/scitranslmed.aad4059.

Abstract

Breast cancer metastatic relapse can occur years after therapy, indicating that disseminated breast cancer cells (BCCs) have a prolonged dormant phase before becoming proliferative. A major site of disease dissemination and relapse is bone, although the critical signals that allow circulating BCCs to identify bone microvasculature, enter tissue, and tether to the microenvironment are poorly understood. Using real-time in vivo microscopy of bone marrow (BM) in a breast cancer xenograft model, we show that dormant and proliferating BCCs occupy distinct areas, with dormant BCCs predominantly found in E-selectin- and stromal cell-derived factor 1 (SDF-1)-rich perisinusoidal vascular regions. We use highly specific inhibitors of E-selectin and C-X-C chemokine receptor type 4 (CXCR4) (SDF-1 receptor) to demonstrate that E-selectin and SDF-1 orchestrate opposing roles in BCC trafficking. Whereas E-selectin interactions are critical for allowing BCC entry into the BM, the SDF-1/CXCR4 interaction anchors BCCs to the microenvironment, and its inhibition induces mobilization of dormant micrometastases into circulation. Homing studies with primary BCCs also demonstrate that E-selectin regulates their entry into bone through the sinusoidal niche, and immunohistochemical staining of patient BMs shows dormant micrometastatic disease adjacent to SDF-1(+) vasculature. These findings shed light on how BCCs traffic within the host, and suggest that simultaneous blockade of CXCR4 and E-selectin in patients could molecularly excise dormant micrometastases from the protective BM environment, preventing their emergence as relapsed disease.

MeSH terms

  • Animals
  • Benzylamines
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Breast Neoplasms / complications*
  • Breast Neoplasms / metabolism*
  • Cell Line, Tumor
  • Chemokine CXCL12 / antagonists & inhibitors
  • Chemokine CXCL12 / metabolism
  • Cyclams
  • E-Selectin / antagonists & inhibitors
  • E-Selectin / metabolism
  • Female
  • Flow Cytometry
  • Heterocyclic Compounds / pharmacology
  • Humans
  • Immunohistochemistry
  • MCF-7 Cells
  • Mice
  • Mice, SCID
  • Microscopy, Confocal
  • Neoplasm Micrometastasis / pathology
  • Neoplasm Micrometastasis / physiopathology
  • Neoplasm Micrometastasis / prevention & control*
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / prevention & control
  • Protein Binding
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, CXCR4 / metabolism
  • Tumor Cells, Cultured

Substances

  • Benzylamines
  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Cyclams
  • E-Selectin
  • Heterocyclic Compounds
  • Receptors, CXCR4
  • plerixafor